Phenylpiracetam

Phenylpiracetam is Piracetam with a phenyl ring at the 4-position. It was characterised in 1983 at the Soviet Institute of Pharmacology, where it was shown to activate operant behaviour more powerfully than piracetam, reverse the depressant effects of diazepam, inhibit post-rotational nystagmus, prevent retrograde amnesia — and, unlike piracetam, to have a specific anticonvulsant action [1].

It is prescribed in Russia as Phenotropil, and more recently as Actitropil, for cerebral ischaemia, asthenia, epilepsy and mental disorders [8]. Outside Russia it has no approval, and it turns up in two other contexts: as a doping agent, and as an unauthorised ingredient in supplements sold as nootropics [4][9].

Phenylpiracetam is the racetam whose mechanism is least like a racetam's. When R-phenylpiracetam was put through radioligand binding and enzyme activity panels, the dopamine transporter was the only significant target found [2]. Earlier work had already identified S-phenylpiracetam as a selective DAT inhibitor that does not act on norepinephrine or serotonin receptors [10].

That is a stimulant mechanism, and it explains the compound's character better than membrane fluidity does.

The enantiomers separate cleanly, which is unusual and informative. In mice, R-phenotropil raised locomotor activity at 10 and 50 mg/kg while the S-isomer needed 50 mg/kg; both produced antidepressant-like effects in forced swim; but only R-phenotropil improved passive avoidance memory, at 1 mg/kg, and the S-isomer was inactive in that test at any dose. Brain concentrations of the two were the same, so the difference is pharmacodynamic [3]. The racemate that people actually take is half an inactive memory compound.

The S-isomer does something else. Given to Western-diet-fed mice for eight weeks and to obese Zucker rats for twelve, it reduced body weight gain and fat mass, lowered plasma glucose and leptin, and improved glucose tolerance — without stimulating locomotor activity [10]. R-phenylpiracetam, meanwhile, attenuated LPS-induced fever and brain TNF-α, IL-1β and iNOS expression, and reduced carrageenan paw oedema [2].

Two Russian preclinical papers bear on how it compares with its parent and on how far the "nootropic" label stretches. In rats given cerebral ischaemia by bilateral carotid occlusion and by craniocaudal gravitational loading, phenotropil reduced neurological deficit, preserved locomotor, exploratory and memory function, improved survival and helped restore local cortical blood flow — and did so more than piracetam did in the same models [11]. Separately, a screen against antipsychotic models found phenotropil active in the apomorphine verticalisation and 5-HTP hyperkinesis tests and antagonising haloperidol catalepsy, without the sedation those drugs cause [12]. Both are animal work from the drug's own research tradition, and neither has been replicated outside it.

No controlled human safety data appears in the references cited here. The 1983 characterisation notes that at high doses the compound produces psychodepressant effects — the opposite of what it does at low ones [1].

The Russian trials report tolerability rather than measuring it formally. In the vertebrobasilar-insufficiency study, 3 of 35 patients on 100 mg daily stopped the drug: two for a rise in blood pressure and one for disturbed sleep [6]. Both are what a dopamine transporter inhibitor would be expected to do, and the hypertension signal matters because the patients taking this drug are being treated for cerebrovascular disease. The stroke-rehabilitation and encephalopathy studies report no adverse events at 400 mg and 200 mg daily [5][13], which is a weaker statement than it looks: neither was designed to collect them systematically.

The practical concerns are regulatory and market-related. Phenylpiracetam has been prohibited in sport since 1998, when fonturacetam became the first nootropic on the banned list [4], and an analytical method for detecting carphedon in human urine was published the following year [15]. Athletes subject to testing should treat any product that might contain it as disqualifying.

A 2020–2024 market surveillance study by twelve official European and Australian medicines control laboratories found phenylpiracetam among the prescription-only Russian drugs intercepted in pharmacological quantities — in some cases as large bulk quantities of raw material — with 69% of samples coming from the illegal market and about half presented as dietary supplements [9]. A 2021 US analysis found phenylpiracetam listed on cognitive-enhancement supplement labels, in a product category where 75% of declared quantities were inaccurate and undeclared unapproved drugs were common [16].